What is Citius Oncology, Inc.'s final milestone payment?

Citius Oncology, Inc. (CTOR) reported final milestone payment of $2.2M in Q4 2025.

What does final milestone payment mean?

The specific financial payment due upon the successful completion of the final regulatory or commercial milestone in a licensing or partnership agreement. This represents the ultimate hurdle payment before a product reaches full commercial maturity or ownership transfer. It is a key indicator of the final cost of acquiring or developing a specific asset.

Citius Oncology, Inc. CTOR Final Milestone Payment

Final Milestone Payment at other companies

OS TherapiesOSTX

$22.38M0.0%

OS TherapiesOSTX

$22.38M0.0%

InsmedINSM

$15M—

Tarsus Pharmaceuticals, Inc.TARS

$20M0.0%

Tarsus Pharmaceuticals, Inc.TARS

$92M—

HRO

HarrowHROW

$1.75M—

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:FinalMilestonePayment.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s final milestone payment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s final milestone payment?: Citius Oncology, Inc. (CTOR) reported final milestone payment of $2.2M in Q4 2025.
What does final milestone payment mean?: The specific financial payment due upon the successful completion of the final regulatory or commercial milestone in a licensing or partnership agreement. This represents the ultimate hurdle payment before a product reaches full commercial maturity or ownership transfer. It is a key indicator of the final cost of acquiring or developing a specific asset.